Transform treatment for people living with cystic fibrosis

Applying a personalized approach to create an effective, accessible next-in-class solution for people with cystic fibrosis

We are FAIR - The company and its origins

Fair Therapeutics was founded in 2021 by two CF professors from Utrecht University, the Netherlands, who saw the need for an alternative treatment for people with cystic fibrosis (PwCF). While an effective CF treatment existed, many PwCF cannot benefit due to mutation type, side effects, lack of response, or unaffordable costs in their country.

Determined to help those left behind, they secured access to promising drugs in development and launched Fair Therapeutics. Their unique approach combines these drugs with a diagnostic tool—an organoid model that mimics personal intestines—developed by one of the professors. This model predicts individual CF drug responses and makes drug development for ultra-rare mutations feasible, even eliminating the need for clinical trials in small patient populations.

Fair Therapeutics is currently participating in the HIT-CF consortium which is conducting a phase 2b study that tests Fair Therapeutics’ three CFTR modulators, and selects trial patients using this organoid model.

Our Team

CEO - Ines Rodriguez Alvarez (PhD, MBA)

Ines joined Fair TX in July 2022 as the Chief Executive Officer. She is an experienced biotech and pharma manager, trained as bioprocess engineer and worked as CMC leader/advisor at J&J, CEPI, Baxter and Crucell among others.

Chief Business Officer - Anne van Loon (MSc)

Experienced strategy consultant from BCG, fulfilled internal strategy roles in industry (e.g. Crucell). Worked as an independent consultant and supported multiple start-ups and scale ups in the biotech and pharmaceutical industry. Supported Fair TX since Q4 2022 and joined Fair TX as Chief Business Officer in July 2024.

Advisor - Mark de Rosch (PhD)

Experienced biotech executive, most recently COO at Aura Biosciences, contributing to Aura becoming a public company and supporting Phase 3-readiness. He has been Chief Regulatory Officer at Epizyme, prior organizations include Akebia Therapeutics, Voisin Consulting Life Sciences, Inspiration Biopharmaceuticals, Vertex Pharmaceuticals, Berlex Laboratories, Diatide, and Mallinckrodt. At Vertex he led the regulatory strategy and marketing approvals for Kalydeco.

Finance Advisor - Liesbeth Tuininga

Global senior finance expert in various industries, including banking, M&A, energy, and sustainable development. Expert advisor on innovative business models.. Has the mentality and the DNA to maximize business value. Drives growth and professionalism whilst building strong organisations. Passionate about innovation and collaboration to make companies thrive.

CSO & Founder - Prof. Jeffrey Beekman

Professor in Cellular Disease Models and affiliated with the University Medical Center Utrecht. Specialised in stem cell-based culture and inventor of the assay technology to model (personalized) treatment of cystic fibrosis. His work has been awarded by the European Respiratory Society, the European CF society and he received the Prix Galien research award in 2019.

Founder, Advisor & Board member - Prof. Kors van der Ent

Pediatrician, Professor in Pediatric Pulmonology and chair of the Child Health Program at the UMC Utrecht. He chairs the CF-group within the European Reference Network for rare lung diseases and is the coordinator of the EC-funded HIT-CF project, which has access to the entire European CF patient population.